Autologous Tumor Rejection in Humans: Trimming the Myths

REFERENCES

• Appay V., Dunbar P. R., Callan M., Klenerman P., Gillespie G. M. A., Papagno L., Ogg G. S., King A., Lechner F., Spina C. A., Little S., Havlir D. V., Richman D. D., Gruener N., Pape G., Waters A., Easterbrook P., Salio M., Cerundolo V., McMichael A., Rowland-Jones S. L. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat. Med 2002; 8(4)379–385, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Atkins M. B., Lotze M. T., Dutcher J. P., Fisher R. I., Weiss G., Margolin K., Abrams J., Sznol M., Parkinson D. R., Hawkins M., Paradise C., Kunkel L., Rosenberg S. A. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol 1998; 17(7)2105–2116, [CSA]
   Web of Science ®Google Scholar
• Badoual C., Hans S., Rodriguez J., Peyrard S., Klein C., Agueznay N. H., Mosseri V., Laccourreye O., Bruneval P., Fridman W. H., Brasnu D. F., Tartour E. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin. Cancer Res 2006; 12(2)465–472, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Boon T., Coulie P., Marchand M., Weynants P., Wolfel T., Brichard V. Genes coding for tumor rejection antigens: perspectives for specific immunotherapy. Important Adv. Oncol 1994; 5: 3–69, [CSA]
   Google Scholar
• Boon T., Coulie P. G., Van den Eynde B. Tumor antigens recognized by T cells. Immunol. Today 1997; 18(6)267–268, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Brander C., O'Connor P., Suscovich T., Jones N. G., Lee Y., Kedes D., Ganem D., Martin J., Osmond D., Southwood S., Sette A., Walker B. D., Scadden D. T. Definition of an optimal cytotoxic T lymphocyte epitope in the latently expressed Kaposi's sarcoma-associated herpesvirus kaposin protein. J Infect Dis 2001; 184(2)119–126, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Champagne P., Ogg G. S., King A., Knabenhans C., Ellefsen K., Nobile M., Appay V., Rizzardi G. P., Fleury S., Lipp M., Forster R., Rowland-Jones S., Sekaly R.-P., McMichael A. J., Pantaleo G. Skewed maturation of memory HIV-specific CD8 T lymphoctes. Nature 2001; 410: 106–111, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Chua D., Huang J., Zheng B., Lau S. Y., Luk W., Kwong D. L., Sham J. S., Moss D., Yuen K. Y., Im S. W., Ng M. H. Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma. Int. J. Cancer 2001; 94(1)73–80, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Conti P., Kempuraj D., Kandere K., Di Gioacchino M., Reale M., Barbacane R. C., Castellani M. L., Mortari U., Boucher W., Letourneau R., Theoharides T. C. Interleukin-16 network in inflammation and allergy. Allergy Asthma Proc 2002; 23(2)103–108, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Cormier J. N., Salgaller M. L., Prevette T., Barracchini K. C., Rivoltini L., Restifo N. P., Rosenberg S. A., Marincola F. M. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A [see comments]. Cancer J. Sci. Am 1997; 3(1)37–44, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Cuenca A., Cheng F., Wang H., Brayer J., Horna P., Gu L., Bien H., Borrello I. M., Levitsky H. I., Sotomayor E. M. Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens. Cancer Res 2003; 63(24)9007–9015, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Curiel T. J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M., Conejo-Garcia J. R., Zhang L., Burow M., Zhu Y., Wei S., Kryczek I., Daniel B., Gordon A., Myers L., Lackner A., Disis M. L., Knutson K. L., Chen L., Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med 2004; 10(9)942–949, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Curtsinger J. M., Johnson C. M., Mescher M. F. CD8 T cell clonal expansion and development of effector function require prolonged exposure to antigen, costimulation, and signal 3 cytokine. J. Immunol 2003; 171(10)5165–5171, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Dunn G. P., Bruce A. T., Ikeda H., Old L. J., Schreiber R. D. Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunol 2002; 3(11)991–998, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Dunn G. P., Old L. J., Schreiber R. D. The three Es of cancer immunoediting. Annu. Rev. Immunol 2004; 22: 329–360, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ensoli B., Sirianni M. C. Kaposi's sarcoma pathogenesis: alink between immunology and tumor biology. Crit. Rev. Oncog 1998; 9(2)107–124, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Fuchs E. J., Matzinger P. Is cancer dangerous to the immune system?. Semin.Immunol 1996; 8(5)271–280, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Gottschalk S., Heslop H. E., Rooney C. M. Treatment of Epstein-Barr virus-associated malignancies with specific T cells. Adv. Cancer Res 2002, 84: 175–201, [CSA]
   PubMedGoogle Scholar
• Green M. Management of Epstein-Barr virus-induced post-tranplant lymphoproliferative disease in recipients of solid organ transplanation. Am. J. Transplant 2001; 1(2)103–108, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Hamann D., Baars P. A., Rep M. H. G., Hoolbrink B., Kerkhof-Garde S. R., Klein M. R., van Lier R. A. W. Phenotype and functional separation of memory and effector human CD8+ T cells. J. Exper. Med 1997; 186(9)1407–1418, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Haque T., Taylor C., Wilkie G. M., Murad P., Amlot P. L., Beath S., McKiernan P. J., Crawford D. H. Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells. Transplantation 2001; 72(8)1399–1402, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Heslop H. E., Rooney C. M. Adoptive cellular immunotherapy for EBV lymphoproliferative disease. Immunol. Rev 1997; 157: 217–222, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Holmes J., Hemmett L., Garfield S. The cost-effectiveness of human papillomavirus screening for cervical cancer. A review of recent modelling studies. Eur. J. Health Econ 2005; 6(1)30–37, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Howell W. M., Bateman A. C., Turner S. J., Collins A., Theaker J. M. Influence of vascular endothelial growth factor single nucleotide polymorphisms on tumour development in cutaneous malignant melanoma. Genes Immun 2002a, 3: 229–232, [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Howell W. M., Calder P. C., Grimble R. F. Gene polymorphisms, inflammatory diseases and cancer. Proc. Nutr. Soc 2002b; 61(4)447–456, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Jin P., Wang E. Polymorphism in clinical immunology. From HLA typing to immunogenetic profiling. J. Transl. Med 2003; 1(8), [CSA]
   PubMedGoogle Scholar
• Kaech S. M., Hemby S., Kersh E., Ahmed R. Molecular and functional profiling of memory CD8 T cell differentiation. Cell 2002; 111: 837–851, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kammula U. S., Lee K.-H., Riker A., Wang E., Ohnmacht G. A., Rosenberg S. A., Marincola F. M. Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. J. Immunol 1999; 163: 6867–6879, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kast W. M., Levitsky H., Marincola F. M. Synopsis of the 6th Walker's Cay Colloquium on cancer vaccines and immunotherapy. J. Transl. Med 2004; 2(1)20, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Khanna R., Bell S., Sherritt M., Galbraith A., Burrows S. R., Rafter L., Clarke B., Slaughter R., Falk M. C., Douglass J., Williams T., Elliott S. L., Moss D. J. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc. Natl. Acad. Sci. USA 1999; 96(18)10391–10396, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Khong H. T., Restifo N. P. Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nature Immunol 2002; 3(11)999–1005, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kim C. J., Parkinson D. R., Marincola F. M. Immunodominance across the HLA polymorphism: implications for cancer immunotherapy. J. Immunother 1997; 21(1)1–16, [CSA]
   Web of Science ®Google Scholar
• Korn E. L., Troendle J. F., McShane L. M., Simon R. Controlling the number of false discoveries: application to high-dimensional genomic data. J. Stat. Plan. Infer 2003; 124(2)379–398, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Kreimer A. R., Clifford G. M., Boyle P., Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol. Biomarkers Prev 2005; 14(2)467–475, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lally K. M., Mocellin S., Ohnmacht G. A., Nielsen M.-B., Bettinotti M., Panelli M. C., Monsurro’ V., Marincola F. M. Unmasking cryptic epitopes after loss of immunodominant tumor antigen expression through epitope spreading. Int. J. Cancer 2001; 93: 841–847, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lang K. S., Recher M., Junt T., Navarini A. A., Harris N. L., Freigang S., Odermatt B., Conrad C., Ittner L. M., Bauer S., Luther S. A., Uematsu S., Akira S., Hengartner H., Zinkernagel R. M. Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat. Med 2005; 11(2)138–145, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Leach D. R., Krummel M. F., Allison J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271(5256)1734–1736, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Lee J. E., Reveille J. D., Ross M. I., Platsoucas C. D. HLA-DQB1*0301 association with increased cutaneous melanoma risk. Int. J. Cancer 1994; 59(4)510–513, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Lee K.-H., Wang E., Nielsen M.-B., Wunderlich J., Migueles S., Connors M., Steinberg S. M., Rosenberg S. A., Marincola F. M. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J. Immunol 1999a; 163: 6292–6300, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Lee P. P., Yee C., Savage P. A., Fong L., Brockstedt D., Weber J. S., Johnson D., Swetter S., Thompson J., Greenberg P. D., Roederer M., Davis M. M. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med 1999b; 5(6)677–685, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lengauer C., Kinzler K. W., Vogelstein B. Genetic instabilities in human cancers. Nature 1998; 396(6712)643–649, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Liu D., O'Day S. J., Yang D., Boasberg P., Milford R., Kristedja T., Groshen S., Weber J. Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study. Clin. Cancer Res 2005; 11(3)1237–1246, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Malyguine A., Strobl S., Shafer-Weaver K., Ulderich T., Troke A., Baseler M., Kwak L., Neelapu S. A modified human ELISPOT assay to detect specific responses to primary tumor cell targets. J. Transl. Med 2004; 2(1)9, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Marincola F. M. Interleukin-2. Biol. Ther. Cancer Updates 1994; 4(3)1–16, [CSA]
   Google Scholar
• Marincola F. M. A balanced review of the status of T cell-based therapy against cancer. J. Transl. Med 2005; 3(1)16, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Marincola F. M., Ferrone S. Immunotherapy of melanoma: the good news, the bad news and what to do next. Sem. Cancer Biol 2003; 13(6)387–389, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Marincola F. M., Jaffe E. M., Hicklin D. J., Ferrone S. Escape of human solid tumors from T cell recognition: molecular mechanisms and functional significance. Adv. Immunol 2000; 74: 181–273, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Marincola F. M., Rivoltini L., Salgaller M. L., Player M., Rosenberg S. A. Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence for in vivo priming by tumor cells. J. Immunother 1996a; 19(4)266–277, [CSA]
   Web of Science ®Google Scholar
• Marincola F. M., Shamamian P., Rivoltini L., Salgaller M. L., Reid J., Restifo N. P., Simonis T. B., Venzon D., White D. E., Parkinson D. R. HLA associations in the anti-tumor response against malignant melanoma. J. Immunother 1996b; 18: 242–252, [CSA]
   Web of Science ®Google Scholar
• Marincola F. M., Wang E., Herlyn M., Seliger B., Ferrone S. Tumors as elusive targets of T cell-directed immunotherapy. Trends Immunol 2003; 24(6)334–341, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Masramon L., Ribas M., Cifuentes P., Arribas R., Garcia F., Egozcue J., Peinado M. A., Miro R. Cytogenetic characterization of two colon cell lines by using conventional G-banding, comparative genomic hybridization, and whole chromosome painting. Cancer Genet Cytogenet 2000; 121(1)17–21, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Matzinger P. An innate sense of danger. Semin. Immunol 1998; 10(5)399–415, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Matzinger P. Danger model of immunity. Scand. J. Immunol 2001; 54(1–2)2–3, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• McKee M. D., Roszkowski J. J., Nishimura M. I. T cell avidity and tumor recognition: implications and therapeutic strategies. J. Transl. Med 2005; 3: 35, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Migueles S. A., Laborico A. C., Shupert W. L., Sabbaghian M. S., Rabin R., Hallahan C. W., van Baarle D., Kostense S., Miedema F., McLaughin M., Ehler L., Liu S., Connors M. HIV-specific CD8+ T cell proliferation is coupled to perforing expression and is maintained in nonprogressors. Nature Immunol 2002; 3(11)1061–1068, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Minev B. R. Melanoma vaccines. Semin. Oncol 2002; 29(5)479–493, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Monsurro’ V., Nagorsen D., Wang E., Provenzano M., Dudley M. E., Rosenberg S. A., Marincola F. M. Functional heterogeneity of vaccine-induced CD8+ T cells. J. Immunol 2002; 168(11)5933–5942, [CSA]
   PubMed Web of Science ®Google Scholar
• Monsurro’ V., Nielsen M.-B., Perez-Diez A., Dudley M. E., Wang E., Rosenberg S. A., Marincola F. M. Kinetics of TCR use in response to repeated epitope-specific immunization. J. Immunol 2001; 166: 5817–5825, [CSA]
   PubMed Web of Science ®Google Scholar
• Monsurro’ V., Wang E., Panelli M. C., Nagorsen D., Jin P., Smith K., Ngalame Y., Even J., Marincola F. M. Active-specific immunization against cancer: is the problem at the receiving end?. Sem. Cancer Biol 2003; 13: 473–480, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Monsurro’ V., Wang E., Yamano Y., Migueles S. A., Panelli M. C., Smith K., Nagorsen D., Connors M., Jacobson S., Marincola F. M. Quiescent phenotype of tumor-specific CD8+ T cells following immunization. Blood 2004; 104(7)1970–1978, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Moss P., Khan N. CD8(+) T-cell immunity to cytomegalovirus. Hum. Immunol 2004; 65(5)456–464, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Nagorsen D., Wang E., Monsurro’ V., Zanovello P., Marincola F. M., Panelli M. C. Polarized monocyte response to cytokine stimulation. Genome Biol 2005; 6: R15, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Neidhardt-Berard E. M., Berard F., Banchereau J., Palucka A. K. Dendritic cells loaded with killed breast cancer cells induce differentiation of tumor-specific cytotoxic T lymphocytes. Breast Cancer Res 2004; 6(4)R322–R328, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Nicol A. F., Fernandes A. T., Bonecini-Almeida M. G. Immune response in cervical dysplasia induced by human papillomavirus: the influence of human immunodeficiency virus-1 co-infection—review. Mem.Inst Oswaldo Cruz 2005; 100(1)1–12, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Nielsen M.-B., Monsurro’ V., Miguelse S., Wang E., Perez-Diez A., Lee K.-H., Kammula U. S., Rosenberg S. A., Marincola F. M. Status of activation of circulating vaccine-elicited CD8+ T cells. J. Immunol 2000; 165(4)2287–2296, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Ochsenbein A. F., Klenerman P., Karrer U., Ludewig B., Pericin M., Hengartner H., Zinkernagel R. M. Immune suerveillance against a solid tumor fails because of immunological ignorance. Proc. Natl. Acad. Sci. USA 1999; 96: 2233–2238, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ohnmacht G. A., Wang E., Mocellin S., Abati A., Filie A., Fetsch P. A., Riker A., Kammula U. S., Rosenberg S. A., Marincola F. M. Short term kinetics of tumor antigen expression in response to vaccination. J. Immunol 2001; 167: 1809–1820, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Old L. J., Chen Y. T. New paths in human cancer serology. J. Exp. Med 1998; 187(8)1163–1167, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Paczesny S., Ueno H., Fay J., Banchereau J., Palucka A. K. Dendritic cells as vectors for immunotherapy of cancer. Sem. Cancer Biol 2003; 13(6)439–447, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Panelli M. C., Martin B., Nagorsen D., Wang E., Smith K., Monsurro’ V., Marincola F. M. A genomic and proteomic-based hypothesis on the eclectic effects of systemic interleukin-2 administration in the context of melanoma-specific immunization. Cells Tissues Organs 2003; 177(3)124–131, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Panelli M. C., Riker A., Kammula U. S., Lee K.-H., Wang E., Rosenberg S. A., Marincola F. M. Expansion of Tumor/T cell pairs from Fine Needle Aspirates (FNA) of Melanoma Metastases. J. Immunol 2000; 164(1)495–504, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Panelli M. C., Wang E., Phan G., Puhlman M., Miller L., Ohnmacht G. A., Klein H., Marincola F. M. Genetic profiling of peripheral mononuclear cells and melanoma metastases in response to systemic interleukin-2 administration. Genome Biol 2002; 3(7), RESEARCH0035[CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Panelli M. C., White R. L., Foster M., Jr., Martin B., Wang E., Smith K., Marincola F. M. Forecasting the cytokine storm following systemic interleukin-2 administration. J. Transl. Med 2004; 2: 17, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Parmiani G., Castelli C., Dalerba P., Mortarini R., Rivoltini L., Marincola F. M., Anichini A. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?. J. Natl. Cancer Inst 2002; 94(11)805–818, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Parmiani G., Castelli C., Rivoltini L., Casati C., Tully G. A., Novellino L., Patuzzo A., Tosi D., Anichini A., Santinami M. Immunotherapy of melanoma. Sem. Cancer Biol 2003; 13(6)391–400, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Perez-Diez A., Spiess P. J., Restifo N. P., Matzinger P., Marincola F. M. Intensity of the vaccine-elicited immune response determines tumor clearance. J. Immunol 2002; 168: 338–347, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Phan G. Q., Touloukian C. E., Yang J. C., Restifo N. P., Sherry R. M., Hwu P., Topalian S. L., Schwartzentruber D. J., Seipp C. A., Freezer L. J., Morton K. E., Mavroukakis S. A., White D. E., Rosenberg S. A. Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. J. Immunother 2003; 26(4)349–356, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Pittet M. J., Speiser D. E., Lienard D., Valmori D., Guillaume P., Dutoit V., Rimoldi D., Lejeune F., Cerottini J. C., Romero P. Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide. Clin. Cancer Res 2001a; 7(3)796s–803s, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Pittet M. J., Speiser D. E., Valmori D., Rimoldi D., Lienard D., Lejeune F., Cerottini J.-C., Romero P. Ex vivo analysis of tumor antigen specific CD8+ T cell responses using MHC/peptide tetramers in cancer patients. Int. Immunopharmacol 2001b; 1(7)1235–1247, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Pittet M. J., Zippelius A., Speiser D. E., Assenmacher M., Guillaume P., Valmori D., Lienard D., Lejune F., Cerottini J.-C., Romero P. Ex vivo IFN-γ secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseases. J. Immunol 2001c; 166: 7634–7640, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Pockaj B. A., Sherry R. M., Wei J. P., Yannelli J. R., Carter C. S., Leitman S. F., Carasquillo J. A., Steinberg S. M., Rosenberg S. A., Yang J. C. Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer 1994; 73: 1731–1737, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Rinaldo C. R., Jr., Torpey D. J., III. Cell-mediated immunity and immunosuppression in herpes simplex virus infection. Immunodeficiency 1993; 5(1)33–90, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Rooney C. M., Roskrow M. A., Smith C. A., Brenner M. K., Heslop H. E. Immunotherapy of Epstein-Barr virus-associated cancer. J. Natl. Cancer Instit. Monogr 1998; 23: 89–93, [CSA]
   PubMedGoogle Scholar
• Rosenberg S. A. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today 1997; 18(4)175–182, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Rosenberg S. A., Lotze M. T., Yang J. C., Aebersold P. M., Linehan W. M., Seipp C. A., White D. E. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg 1989; 210: 474–484, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A., Yang J. C., Schwartzentruber D., Hwu P., Marincola F. M., Topalian S. L., Restifo N. P., Dufour E., Schwartzberg L., Spiess P., Wunderlich J., Parkhurst M. R., Kawakami Y., Seipp C., Einhorn J. H., White D. Immunologic and therapeutic evaluation of a synthetic tumor associated peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med 1998; 4(3)321–327, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Rubin J. T., Adams S. D., Simonis T., Lotze M. T. HLA polymorphism and response to IL-2 bases therapy in patients with melanoma. Society for Biological Therapy 1991 Annual Meeting. 1991. 1: 18
   Google Scholar
• Rubio V., Stuge T. B., Singh N., Betts M. R., Weber J. S., Roederer M., Lee P. P. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat. Med 2003; 9(11)1377–1382, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sallusto F., Lenig D., Forster R., Lipp M., Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401(6754)659–660, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sarwal M., Chua M. S., Kambham N., Hsieh S. C., Satterwhite T., Masek M., Salvatierra O., Jr. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N. Engl. J. Med 2003; 349(2)125–138, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Scheibenbogen C., Letsch A., Schmittel A., Asemissen A. M., Thiel E., Keilholz U. Rational peptide-based tumor vaccine development and T cell monitoring. Sem. Cancer Biol 2003; 13(6)423–429, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Shafer-Weaver K., Sayers T., Strobl S., Derby E., Ulderich T., Baseler M., Malyguine A. The Granzyme B ELISPOT assay: an alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity. J. Transl. Med 2003; 1(1)14, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Slingluff C. L., Jr., Petroni G. R., Yamshchikov G. V., Hibbitts S., Grosh W. W., Chianese-Bullock K. A., Bissonette E. A., Barnd D. L., Deacon D. H., Patterson J. W., Parekh J., Neese P. Y., Woodson E. M., Wiernasz C. J., Merrill P. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J. Clin. Oncol 2004; 22(22)4474–4485, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Slingluff C. L., Jr., Speiser D. E. Progress and controversies in developing cancer vaccines. J. Transl. Med 2005; 3: 18, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Somasundaram R., Caputo L., Guerry D., Herlyn D. CD8+, HLA-unrestricted, cytotoxic T-lymphocyte line against malignant melanoma. J. Transl. Med 2005; 3: 41, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Speiser D. E., Colonna M., Ayyoub M., Cella M., Pittet M. J., Batard P., Valmori D., Guillaume P., Lienard D., Cerottini J. C., Romero P. The activatory receptor 2B4 is expressed in vivo by human CD8+ effector alpha beta T cells. J. Immunol 2001; 167(11)6165–6170, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Speiser D. E., Pittet M. J., Rimoldi D., Guillame P., Luescher I. F., Lienard D., Lejeune F., Cerottini J.-C., Romero P. Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor specific T cells. Sem Cancer Biol 2003a; 13(6)461–472, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Speiser D. E., Pittet M. J., Rimoldi D., Guillaume P., Luescher I. F., Lienard D., Lejeune F., Cerottini J. C., Romero P. Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells. Semin. Cancer Biol 2003b; 13(6)461–472, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Straathof K. C., Bollard C. M., Popat U., Huls M. H., Lopez T., Morriss M. C., Gresik M. V., Gee A. P., Russell H. V., Brenner M. K., Rooney C. M., Heslop H. E. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 2005; 105(5)1898–1904, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Stroncek D. F., Basil C., Nagorsen D., Deola S., Arico E., Smith K., Wang E., Marincola F. M., Panelli M. C. Delayed polarization of mononuclear phagocyte transcriptional program by type I interferon isoforms. J. Transl. Med 2005; 3(1)24, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Talebi T., Weber J. S. Peptide vaccine trials for melanoma: preclinical background and clinical results. Sem. Cancer Biol 2003; 13(6)431–438, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Terabe M., Berzofsky J. A. Immunoregulatory T cells in tumor immunity. Curr. Opin. Immunol 2004; 16(2)157–162, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Thor Straten P., Schrama D. D., Andersen M. H., Becker J. C. T cell clonotypes in cancer. J. Transl. Med 2004; 2(1)11, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Tomaru U., Yamano Y., Nagai M., Maric D., Kaumaya P. T., Biddison W., Jacobson S. Detection of virus-specific T cells and CD8+ T-cell epitopes by acquisition of peptide-HLA-GFP complexes: analysis of T-cell phenotype and function in chronic viral infections. Nat. Med 2003; 9(4)469–476, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Trofe J., Beebe T. M., Buell J. F., Hanaway M. J., First M. R., Alloway R. R., Gross T. G., Woodle E. S. Posttransplant malignancy. Prog. Transplant 2004; 14(3)193–200, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Urosevic M., Maier T., Benninghoff B., Slade H., Burg G., Dummer R. Mechanisms unerlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch. Dermatol 2003; 139(10)1325–1332, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• van Baarle D., Kostense S., van Oers M. H. J., Miedema F. Failing immune control as a result of impaired CD8+ T-cell maturation: CD27 might provide a clue. Trends Immunol 2002; 23(12)586–591, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Viguier M., Lemaitre F., Verola O., Cho M. S., Gorochov G., Dubertret L., Bachelez H., Kourilsky P., Ferradini L. Foxp3 expressing CD4 + CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J. Immunol 2004; 173(2)1444–1453, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Wang E., Miller L. D., Ohnmacht G. A., Mocellin S., Petersen D., Zhao Y., Simon R., Powell J. I., Asaki E., Alexander H. R., Duray P. H., Herlyn M., Restifo N. P., Liu E. T., Rosenberg S. A., Marincola F. M. Prospective molecular profiling of subcutaneous melanoma metastases suggests classifiers of immune responsiveness. Cancer Res 2002; 62: 3581–3586, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Wang E., Marincola F. M., Stroncek D. Human leukocyte antigen (HLA) and Human Neutrophil Antigen (HNA) systems. Hematology: Basic Principles and Practice4th, R. Hoffman. Elsevier Science, Philadelphia, PA 2005; 2401–2432
   Google Scholar
• Wang E., Panelli M. C., Zavaglia K., Mandruzzato S., Hu N., Taylor P. R., Seliger B., Zanovello P., Freedman R. S., Marincola F. M. Melanoma-restricted genes. J. Transl. Med 2004; 2: 34, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Wherry E. J., Teichgraber V., Becker T. C., Masopust D., Kaech S. M., Antia R., von Andrian U. H., Ahmed R. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nature Immunol 2003; 4(3)225–234, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Wolfel T., Klehmann E., Muller C., Schutt K. H., Meyer zum Buschenfelde K. H., Knuth A. Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J. Exper. Med 1989; 170: 797–810, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Woo E. Y., Yeh H., Chu C. S., Schlienger K., Carroll R. G., Riley J. L., Kaiser L. R., June C. H. Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol 2002; 168(9)4272–4276, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Yamaguchi T., Sakaguchi S. Regulatory T cells in immune surveillance and treatment of cancer. Semin. Cancer Biol 2005, [CSA]
   Web of Science ®Google Scholar
• Yee C. Adoptive T cell therapy: addressing challenges in cancer immunotherapy. J. Transl. Med 2005; 3: 17, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Zea A. H., Curti B. D., Longo D. L., Alvord W. G., Strobl S. L., Mizoguchi H., Creekmore S. P., O'shea J. J., Powers G. C., Urba W. J., Ochoa A. C. Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin. Cancer Res 1995; 1: 1327–1335, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar